Do analysts rate CRVL or CSTL?

Castle Biosciences has a consensus target price of $42.00, indicating a potential upside of 27.62%. Given Castle Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Castle Biosciences is more favorable than CorVel. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CorVel 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Castle Biosciences 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.80

Which has preferable earnings and valuation, CRVL or CSTL?

CorVel has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than CorVel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CorVel $958.53M 3.63 $110.34M $2.25 30.32 Castle Biosciences $344.23M 2.92 -$24.16M -$0.66 N/A

Does the media favor CRVL or CSTL?

In the previous week, CorVel and CorVel both had 8 articles in the media. Castle Biosciences' average media sentiment score of 1.06 beat CorVel's score of 0.86 indicating that Castle Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorVel 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Castle Biosciences 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CSTL or OPCH?

In the previous week, Castle Biosciences had 4 more articles in the media than Option Care Health. MarketBeat recorded 8 mentions for Castle Biosciences and 4 mentions for Option Care Health. Option Care Health's average media sentiment score of 1.13 beat Castle Biosciences' score of 1.06 indicating that Option Care Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Castle Biosciences 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Option Care Health 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CSTL or AVAH?

In the previous week, Castle Biosciences and Castle Biosciences both had 8 articles in the media. Aveanna Healthcare's average media sentiment score of 1.16 beat Castle Biosciences' score of 1.06 indicating that Aveanna Healthcare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Castle Biosciences 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aveanna Healthcare 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CSTL or PRVA?

In the previous week, Privia Health Group had 2 more articles in the media than Castle Biosciences. MarketBeat recorded 10 mentions for Privia Health Group and 8 mentions for Castle Biosciences. Privia Health Group's average media sentiment score of 1.52 beat Castle Biosciences' score of 1.06 indicating that Privia Health Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Castle Biosciences 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Privia Health Group 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable valuation and earnings, WGS or CSTL?

GeneDx has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeneDx $427.54M 6.00 -$21.02M -$3.64 N/A Castle Biosciences $344.23M 2.92 -$24.16M -$0.66 N/A

Castle Biosciences (CSTL) Competitors

$32.91 +0.26 (+0.80%)

As of 04:00 PM Eastern

Compare

CSTL vs. CRVL, OPCH, AVAH, PRVA, and WGS

Should you buy Castle Biosciences stock or one of its competitors? Castle Biosciences's main competitors and comparable companies include CorVel (CRVL), Option Care Health (OPCH), Aveanna Healthcare (AVAH), Privia Health Group (PRVA), and GeneDx (WGS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Castle Biosciences compare to CorVel?

CorVel (NASDAQ:CRVL) and Castle Biosciences (NASDAQ:CSTL) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

CorVel has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Castle Biosciences has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market.

Castle Biosciences has a consensus target price of $42.00, indicating a potential upside of 27.62%. Given Castle Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Castle Biosciences is more favorable than CorVel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorVel	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, CorVel and CorVel both had 8 articles in the media. Castle Biosciences' average media sentiment score of 1.06 beat CorVel's score of 0.86 indicating that Castle Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorVel	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Castle Biosciences	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CorVel has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than CorVel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorVel	$958.53M	3.63	$110.34M	$2.25	30.32
Castle Biosciences	$344.23M	2.92	-$24.16M	-$0.66	N/A

51.4% of CorVel shares are held by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are held by institutional investors. 39.7% of CorVel shares are held by company insiders. Comparatively, 6.1% of Castle Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

CorVel has a net margin of 11.72% compared to Castle Biosciences' net margin of -5.43%. CorVel's return on equity of 29.92% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorVel	11.72%	29.92%	17.82%
Castle Biosciences	-5.43%	-4.15%	-3.45%

Summary

CorVel beats Castle Biosciences on 9 of the 16 factors compared between the two stocks.

How does Castle Biosciences compare to Option Care Health?

Castle Biosciences (NASDAQ:CSTL) and Option Care Health (NASDAQ:OPCH) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

92.6% of Castle Biosciences shares are held by institutional investors. Comparatively, 98.1% of Option Care Health shares are held by institutional investors. 6.1% of Castle Biosciences shares are held by insiders. Comparatively, 1.7% of Option Care Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Castle Biosciences has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market. Comparatively, Option Care Health has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Option Care Health has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Option Care Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Castle Biosciences	$344.23M	2.92	-$24.16M	-$0.66	N/A
Option Care Health	$5.65B	0.64	$207.59M	$1.33	18.20

In the previous week, Castle Biosciences had 4 more articles in the media than Option Care Health. MarketBeat recorded 8 mentions for Castle Biosciences and 4 mentions for Option Care Health. Option Care Health's average media sentiment score of 1.13 beat Castle Biosciences' score of 1.06 indicating that Option Care Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Castle Biosciences	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Option Care Health	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Option Care Health has a net margin of 3.68% compared to Castle Biosciences' net margin of -5.43%. Option Care Health's return on equity of 18.74% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Castle Biosciences	-5.43%	-4.15%	-3.45%
Option Care Health	3.68%	18.74%	7.25%

Castle Biosciences presently has a consensus price target of $42.00, indicating a potential upside of 27.62%. Option Care Health has a consensus price target of $29.92, indicating a potential upside of 23.60%. Given Castle Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Castle Biosciences is more favorable than Option Care Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Option Care Health	1 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Option Care Health beats Castle Biosciences on 9 of the 16 factors compared between the two stocks.

How does Castle Biosciences compare to Aveanna Healthcare?

Castle Biosciences (NASDAQ:CSTL) and Aveanna Healthcare (NASDAQ:AVAH) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Castle Biosciences currently has a consensus price target of $42.00, indicating a potential upside of 27.62%. Aveanna Healthcare has a consensus price target of $13.50, indicating a potential downside of 0.59%. Given Castle Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Castle Biosciences is more favorable than Aveanna Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Aveanna Healthcare	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.67

Aveanna Healthcare has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Aveanna Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Castle Biosciences	$344.23M	2.92	-$24.16M	-$0.66	N/A
Aveanna Healthcare	$2.43B	1.22	$225.03M	$1.23	11.04

Aveanna Healthcare has a net margin of 10.56% compared to Castle Biosciences' net margin of -5.43%. Aveanna Healthcare's return on equity of 80.70% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Castle Biosciences	-5.43%	-4.15%	-3.45%
Aveanna Healthcare	10.56%	80.70%	7.42%

92.6% of Castle Biosciences shares are owned by institutional investors. Comparatively, 88.0% of Aveanna Healthcare shares are owned by institutional investors. 6.1% of Castle Biosciences shares are owned by company insiders. Comparatively, 5.3% of Aveanna Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Castle Biosciences and Castle Biosciences both had 8 articles in the media. Aveanna Healthcare's average media sentiment score of 1.16 beat Castle Biosciences' score of 1.06 indicating that Aveanna Healthcare is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Castle Biosciences	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aveanna Healthcare	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Castle Biosciences has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market. Comparatively, Aveanna Healthcare has a beta of 1.97, meaning that its stock price is 97% more volatile than the broader market.

Summary

Aveanna Healthcare beats Castle Biosciences on 9 of the 15 factors compared between the two stocks.

How does Castle Biosciences compare to Privia Health Group?

Castle Biosciences (NASDAQ:CSTL) and Privia Health Group (NASDAQ:PRVA) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

In the previous week, Privia Health Group had 2 more articles in the media than Castle Biosciences. MarketBeat recorded 10 mentions for Privia Health Group and 8 mentions for Castle Biosciences. Privia Health Group's average media sentiment score of 1.52 beat Castle Biosciences' score of 1.06 indicating that Privia Health Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Castle Biosciences	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Privia Health Group	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Castle Biosciences currently has a consensus target price of $42.00, indicating a potential upside of 27.62%. Privia Health Group has a consensus target price of $31.00, indicating a potential upside of 50.05%. Given Privia Health Group's higher possible upside, analysts plainly believe Privia Health Group is more favorable than Castle Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Privia Health Group	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.79

Privia Health Group has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Privia Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Castle Biosciences	$344.23M	2.92	-$24.16M	-$0.66	N/A
Privia Health Group	$2.12B	1.24	$22.92M	$0.21	98.38

Privia Health Group has a net margin of 1.19% compared to Castle Biosciences' net margin of -5.43%. Privia Health Group's return on equity of 3.52% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Castle Biosciences	-5.43%	-4.15%	-3.45%
Privia Health Group	1.19%	3.52%	2.00%

Castle Biosciences has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, Privia Health Group has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

92.6% of Castle Biosciences shares are owned by institutional investors. Comparatively, 94.5% of Privia Health Group shares are owned by institutional investors. 6.1% of Castle Biosciences shares are owned by insiders. Comparatively, 5.7% of Privia Health Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Privia Health Group beats Castle Biosciences on 12 of the 17 factors compared between the two stocks.

How does Castle Biosciences compare to GeneDx?

GeneDx (NASDAQ:WGS) and Castle Biosciences (NASDAQ:CSTL) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

GeneDx currently has a consensus price target of $89.57, suggesting a potential upside of 4.16%. Castle Biosciences has a consensus price target of $42.00, suggesting a potential upside of 27.62%. Given Castle Biosciences' higher possible upside, analysts clearly believe Castle Biosciences is more favorable than GeneDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Castle Biosciences had 8 more articles in the media than GeneDx. MarketBeat recorded 8 mentions for Castle Biosciences and 0 mentions for GeneDx. GeneDx's average media sentiment score of 1.30 beat Castle Biosciences' score of 1.06 indicating that GeneDx is being referred to more favorably in the media.

Company	Overall Sentiment
GeneDx	Positive
Castle Biosciences	Positive

61.7% of GeneDx shares are owned by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are owned by institutional investors. 25.2% of GeneDx shares are owned by insiders. Comparatively, 6.1% of Castle Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

GeneDx has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54M	6.00	-$21.02M	-$3.64	N/A
Castle Biosciences	$344.23M	2.92	-$24.16M	-$0.66	N/A

GeneDx has a beta of 1.99, meaning that its share price is 99% more volatile than the broader market. Comparatively, Castle Biosciences has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market.

Castle Biosciences has a net margin of -5.43% compared to GeneDx's net margin of -23.41%. GeneDx's return on equity of 4.12% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-23.41%	4.12%	2.26%
Castle Biosciences	-5.43%	-4.15%	-3.45%

Summary

GeneDx beats Castle Biosciences on 10 of the 15 factors compared between the two stocks.

Get Castle Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CSTL vs. The Competition

Export

Metric	Castle Biosciences	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.01B	$10.00B	$7.17B	$12.89B
Dividend Yield	N/A	2.56%	2.53%	8.57%
P/E Ratio	-49.86	34.60	273.00	25.40
Price / Sales	2.92	4.97	618.40	98.88
Price / Cash	30.02	120.90	77.82	52.27
Price / Book	2.14	3.99	12.86	6.17
Net Income	-$24.16M	$313.25M	$3.47B	$349.50M
7 Day Performance	-1.76%	1.17%	1.27%	-0.05%
1 Month Performance	5.55%	0.40%	5.84%	0.80%
1 Year Performance	42.53%	15.62%	25.77%	15.58%

Castle Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CSTL Castle Biosciences	3.2559 of 5 stars	$32.91 +0.8%	$42.00 +27.6%	+40.7%	$1.01B	$344.23M	N/A	540	Positive News Insider Trade
CRVL CorVel	1.4204 of 5 stars	$69.53 -2.4%	N/A	-21.2%	$3.55B	$983.74M	30.90	5,239	Positive News Analyst Upgrade Insider Trade
OPCH Option Care Health	4.2018 of 5 stars	$23.41 -1.1%	$29.92 +27.8%	-15.5%	$3.50B	$5.65B	17.59	8,266
AVAH Aveanna Healthcare	3.7296 of 5 stars	$13.53 -1.3%	$12.89 -4.7%	+63.5%	$2.95B	$2.43B	11.00	35,500	Gap Up
PRVA Privia Health Group	4.4287 of 5 stars	$20.87 -0.7%	$31.00 +48.6%	-10.8%	$2.67B	$2.12B	99.36	1,226	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CSTL) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Castle Biosciences (CSTL) Competitors

CSTL vs. CRVL, OPCH, AVAH, PRVA, and WGS

How does Castle Biosciences compare to CorVel?

Summary

How does Castle Biosciences compare to Option Care Health?

Summary

How does Castle Biosciences compare to Aveanna Healthcare?

Summary

How does Castle Biosciences compare to Privia Health Group?

Summary

How does Castle Biosciences compare to GeneDx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSTL vs. The Competition

Castle Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Castle Biosciences (CSTL) Competitors

CSTL vs. CRVL, OPCH, AVAH, PRVA, and WGS

How does Castle Biosciences compare to CorVel?

Which has more volatility and risk, CRVL or CSTL?

Do analysts rate CRVL or CSTL?

Does the media favor CRVL or CSTL?

Which has preferable earnings and valuation, CRVL or CSTL?

Do institutionals & insiders hold more shares of CRVL or CSTL?

Is CRVL or CSTL more profitable?

Summary

How does Castle Biosciences compare to Option Care Health?

Do institutionals and insiders believe in CSTL or OPCH?

Which has more volatility & risk, CSTL or OPCH?

Which has preferable valuation & earnings, CSTL or OPCH?

Does the media prefer CSTL or OPCH?

Is CSTL or OPCH more profitable?

Do analysts recommend CSTL or OPCH?

Summary

How does Castle Biosciences compare to Aveanna Healthcare?

Do analysts prefer CSTL or AVAH?

Which has stronger valuation and earnings, CSTL or AVAH?

Is CSTL or AVAH more profitable?

Do institutionals & insiders believe in CSTL or AVAH?

Does the media prefer CSTL or AVAH?

Which has more volatility & risk, CSTL or AVAH?

Summary

How does Castle Biosciences compare to Privia Health Group?

Does the media refer more to CSTL or PRVA?

Do analysts recommend CSTL or PRVA?

Which has stronger earnings and valuation, CSTL or PRVA?

Is CSTL or PRVA more profitable?

Which has more risk & volatility, CSTL or PRVA?

Do institutionals and insiders believe in CSTL or PRVA?

Summary

How does Castle Biosciences compare to GeneDx?

Do analysts recommend WGS or CSTL?

Does the media favor WGS or CSTL?

Do institutionals & insiders hold more shares of WGS or CSTL?

Which has preferable valuation and earnings, WGS or CSTL?

Which has more risk and volatility, WGS or CSTL?

Is WGS or CSTL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSTL vs. The Competition

Castle Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools